The compound’s selective inhibition of PDGFR, with no activity on FLT3, highlights its potential as a targeted therapy for PDGFR-driven cancers: such as non-small cell lung cancers, gastrointestinal stromal tumors, and ovarian cancers. This evidence concerns the gene FLT3 and non-small cell lung carcinoma.